Search research articles
Contact Us
Filters
Showing results (501-510 of 527) with videos related to
Page
of 53
Sort By:
The Lancet. Oncology
|
December 16, 2021
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Thomas Yau, Joong-Won Park, Richard S Finn, et al.
Neuroimage
|
October 18, 2016
Multisite reliability of MR-based functional connectivity
Stephanie Noble, Dustin Scheinost, Emily S Finn, et al.
Journal of the American Society of Nephrology : JASN
|
July 1, 2018
<i>GAPVD1</i> and <i>ANKFY1</i> Mutations Implicate RAB5 Regulation in Nephrotic Syndrome
Tobias Hermle, Ronen Schneider, David Schapiro, et al.
Journal of Hepatology
|
August 14, 2025
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma
Tim Meyer, Richard S Finn, Mitesh Borad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 29, 2017
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Milind Javle, Maeve Lowery, Rachna T Shroff, et al.
Liver Cancer
|
August 20, 2025
Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study
Yoon Jun Kim, Philippe Merle, Richard S Finn, et al.
Gastroenterology
|
September 15, 2022
Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma
Philipp K Haber, Florian Castet, Miguel Torres-Martin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 28, 2024
Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab
Ying-Chun Shen, Tsung-Hao Liu, Alan Nicholas, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
June 2, 2022
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors
Stephen L Chan, Martin Schuler, Yoon-Koo Kang, et al.
Nature Communications
|
September 8, 2020
Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring
Na Sun, Yi-Te Lee, Ryan Y Zhang, et al.
Page
of 53
Search research articles
Search
Showing results (501-510 of 527) with videos related to
Sort By:
Page
of 53
The Lancet. Oncology
|
December 16, 2021
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Thomas Yau, Joong-Won Park, Richard S Finn, et al.
Neuroimage
|
October 18, 2016
Multisite reliability of MR-based functional connectivity
Stephanie Noble, Dustin Scheinost, Emily S Finn, et al.
Journal of the American Society of Nephrology : JASN
|
July 1, 2018
<i>GAPVD1</i> and <i>ANKFY1</i> Mutations Implicate RAB5 Regulation in Nephrotic Syndrome
Tobias Hermle, Ronen Schneider, David Schapiro, et al.
Journal of Hepatology
|
August 14, 2025
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma
Tim Meyer, Richard S Finn, Mitesh Borad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 29, 2017
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Milind Javle, Maeve Lowery, Rachna T Shroff, et al.
Liver Cancer
|
August 20, 2025
Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study
Yoon Jun Kim, Philippe Merle, Richard S Finn, et al.
Gastroenterology
|
September 15, 2022
Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma
Philipp K Haber, Florian Castet, Miguel Torres-Martin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 28, 2024
Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab
Ying-Chun Shen, Tsung-Hao Liu, Alan Nicholas, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
June 2, 2022
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors
Stephen L Chan, Martin Schuler, Yoon-Koo Kang, et al.
Nature Communications
|
September 8, 2020
Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring
Na Sun, Yi-Te Lee, Ryan Y Zhang, et al.
Page
of 53